Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557268 · ClinicalTrials.gov registry record
Pubertal Blockade and Hormone Therapy in Transgender Youth
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 19
- Enrollment target
NCT03557268 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants.
The verdict
NCT03557268 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness, mitochondrial function and the microbiome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2020-09-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557268
The ClinicalTrials.gov registry entry for NCT03557268 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03557268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03557268 about?
NCT03557268 is a clinical study titled "Pubertal Blockade and Hormone Therapy in Transgender Youth". This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory...
What is the current status of trial NCT03557268?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2018-06-19. Estimated completion is 2020-09-09.
Who is sponsoring clinical trial NCT03557268?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.